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Video-Assisted Thoracic Surgery (VATS) Lobectomy for 
Pathologic Stage I Non-Small Cell Lung Cancer: 
A Comparative Study with Thoracotomy Lobectomy
Joon  Suk  Park,  M.D.*,  Kwhanmien  Kim,  M.D.*,  Min  Suk  Choi,  M.D.*, 
Sung  Wook  Chang,  M.D.*,  Woo-sik  Han,  M.D.*
Background:  Surgical treatment of stage I non-small cell lung cancer (NSCLC) can be performed either by thor-
acotomy or by employing video-assisted thoracic surgery (VATS). The aim of this study was to evaluate the feasi-
bility of VATS lobectomy for pathologic stage I NSCLC. Material and Methods: Between December 2003 and 
December 2007, 529 patients with pathologic stage I NSCLC underwent lobectomies (373 thoracotomy, 156 VATS). 
Patients in both groups were selected after being matched by age, gender and pathologic stage using propensity 
score method, to create two comparable groups: thoracotomy and VATS groups, and the overall survival, re-
currence-free survival, complication and length of hospitalization were compared between these two groups.   
Results: After the patients were matched by age, gender and pathologic stage, 272 patients remained eligible for 
analysis, 136 in each group (mean age of 59.5 years; 70 men, 66 women; 80 stage IA, 56 stage IB). There was 
no statistical difference in other preoperative clinical characteristics between the two groups. No hospital mortality 
was observed in both groups. Overall 3-year survival rate was 97.4% in thoracotomy group and 96.6% in VATS 
groups (p=0.76). During the follow-up, 20 patients (14.7%) developed recurrence in thoracotomy group, including lo-
co-regional recurrence in 7, distant metastasis in 13. In VATS group, 13 patients (9.6%) developed recurrence, in-
cluding loco-regional recurrence in 4, distant metastasis in 9. Three-year recurrence-free survival rate was 81.8% in 
thoracotomy group and 85.3% in VATS groups (p=0.43). There was no significant difference in postoperative com-
plications between thoracotomy and VATS groups (30 cases in 22 patients vs. 19 cases in 17 patients, p=0.65, 
odds ratio=1.19). The mean hospital stay of VATS group was 2 days shorter than that of thoracotomy group 
(8.8±6.5 days vs. 6.3±3.3 days, p＜0.05).  Conclusion: VATS lobectomy for pathologic stage I lung cancer is a 
feasible operation with shorter hospitalization, while surgical outcome is comparable to thoracotomy lobectomy.
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INTRODUCTION
Since  video-assisted  thoracoscopic  surgery  (VATS)  lobec-
tomy  was  introduced  in  the  early  1990s,  its  use  in  the  treat-
ment of non-small cell lung cancer (NSCLC) has been gradu-
ally increased. Many surgeons demonstrated the technical fea-VATS Lobectomy for Pathologic Stage I Non-Small Cell Lung Cancer
− 33  −
Table 1. Patients’ characteristics of each group
VATS  (n=136)
Open-thoracotomy 
(n=136)
Median  follow-up  (months)
Age  (years)
Sex  (M : F)
Pathologic  stage  (IA : IB)
Comorbidity
Hypertension
DM
CAD
Pulmonary  disease
  (IPF,  Tbc,  etc)
Previous  pulmonary
  procedure
Others  (trauma,  minor
  surgery,  etc)
Pathology
Adenocarcinoma
Squamous  cell  carcinoma
Bronchioalveolar
  carcinoma
Other  non-small  cell
  lung  cancer
Adjuvant  treatment
Chemotherapy
Radiotherapy
Chemoradiation
No  adjuvant  treatment
24.6±12.1 
(2.0∼58.2)
59.5±8.6
(40∼79)
70 : 66
80 : 56
  6
  5
  1
  4
  2
  4
 9 2
 1 8
 2 0
  6
 2 3
  0
  0
113
30.9±13.4 
(2.6∼57.8)
59.5±9.3 
(40∼79)
70 : 66
80 : 56
 1 0
  1
  2
  3
  1
 1 2
 8 8
 2 7
 2 0
  1
 2 1
  1
  1
113
VATS=Video-assisted  thoracic  surgery;  DM=Diabetes  mellitus; 
CAD=Coronary  artery  disease;  IPF=Interstitial  pulmonary  fib-
rosis;  Tbc=Tuberculosis.
sibility  and  safety  of  VATS  lobectomy.  The  ‘Cancer  and 
Leukemia Group B (CALGB) 39802 prospective multi-institu-
tional  feasibility  study’  revealed  that  VATS  lobectomy  could 
be  performed  with  low  morbidity  and  mortality,  and  a  recent 
meta-analysis  of  various  trials  on  safety  and  efficacy  of 
VATS  lobectomy  demonstrated  that  VATS  lobectomy  is  an 
appropriate  procedure  for  selected  patients  with  early-stage 
NSCLC  when  compared  with  open  surgery.  However,  some 
surgeons  have  been  concerned  about  whether  VATS  lobec-
tomy  really  can  achieve  equal,  or  even  superior,  surgical  and 
oncological  results  compared  with  those  of  conventional 
open-thoracotomy  lobectomy.  This  might  well  be  why  VATS 
lobectomy  is  applied  only  in  less  than  20%  of  lobectomies 
performed  in  the  United  States,  even  though  the  detection  of 
early  lung  cancer  has  been  gradually  increasing  [1].  There-
fore, evidence-based information on VATS lobectomy, regard-
ing  not  only  the  safety  and  technical  feasibility  but  also  the 
oncological  outcome,  should  be  accumulated  more  for  this 
novel  approach  widely  accepted  as  a  standard  procedure  for 
early-stage  NSCLC.
In  our  institution,  VATS  lobectomy  was  adopted  in  the 
early 2000s, and has been performed with a gradual increase, 
for  the  treatment  of  both  benign  lung  disease  and  early-stage 
non-small  cell  lung  cancer.  The  aim  of  this  study  is  to  eval-
uate the feasibility and surgical outcome of VATS lobectomy 
compared  to  conventional  open-thoracotomy,  based  on  our 
experience  of  pathologic  stage  I  NSCLC.
MATERIAL AND METHODS
Between  December  2003  and  December  2007,  medical  re-
cords of patients, who underwent surgery for pathologic stage 
I  NSCLC  in  our  institute,  were  retrospectively  reviewed.  We 
determined  the  cancer  stage  according  to  the  ‘6
th  Edition  of 
TNM  staging  system  of  lung  cancer’,  which  was  suggested 
by  the  International  Staging  Committee  (ISC)  in  the  Interna-
tional  Association  for  the  Study  of  Lung  Cancer  (IASLC). 
This  study  was  reviewed  and  approved  by  the  Institutional 
R e v i e w  B o a r d  o f  o u r  i n s t i t u t e .
To create two comparable groups, we conducted propensity 
score analysis using nearest neighbor matching method of co-
variates  without  replacement.  Verified  independent  variables 
are age, gender, and pathologic stage. Preoperative pulmonary 
function,  postoperative  adjuvant  therapy  and  pre-existing 
co-morbidities  of  patients  were  compared  to  confirm  that 
these  two  groups  are  nearly  identical  except  for  the  surgical 
approaches  (i.e.  VATS  or  open-thoracotomy).  However,  be-
cause  adenocarcinoma  tends  to  be  indicated  more  frequently 
for  VATS  lobectomy,  patients  could  not  be  exactly  matched 
by  tumor  pathology.  The  early  postoperative  results,  such  as 
postoperative  complications,  hospital  stay,  recurrence  pattern, 
and  overall  and  recurrence-free  survival,  were  compared  be-
tween these two groups. Table 1 shows patient characteristics 
of  each  group.Joon Suk Park, et al
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The  decision  to  perform  either  VATS  or  open-thoracotomy 
was  made  by  the  individual  four  thoracic  surgeons  in  our 
institution.  Candidates  for  VATS  lobectomy  were  patients 
with  clinical  stage  I,  peripheral,  small-sized  (≤5  cm)  tumor 
without  endobronchial  lesion.  The  preoperative  workup  in-
cluded  pulmonary  function  tests,  CT  scan,  integrated  positron 
emission  tomography  (PET),  and  computerized  tomography 
(CT)  scan.  For  patients  with  preoperatively  proven  NSCLC, 
mediastinoscopic lymph node biopsy was routinely performed 
regardless  of  CT  or  PET  scan  findings.
All patients received operation under a standard general an-
esthesia protocol, with single lung ventilation by a double-lu-
men endotracheal tube. VATS lobectomy was performed after 
making two ports and a utility incision without rib spreading. 
A 15-mm trocar was introduced through the seventh or eighth 
intercostal  space  for  the  10-mm,  30-degree  thoracoscope.  A 
utility  incision  of  four  to  five  centimeters,  which  was  cen-
tered  on  the  anterior  axillary  line,  was  made  through  the 
fourth  or  fifth  intercostal  space.  A  5∼10  mm  additional  tro-
car  was  placed  through  the  sixth  or  seventh  intercostal  space 
on  the  posterior  scapular  line.  The  target  vessels  were  in-
dividually  dissected,  and  divided using  endoscopic  staplers  or 
surgical clips. The bronchi of target lobes were dissected, and 
divided  using  endoscopic  staplers.  All  specimens  were  put  in 
an impermeable bag and removed through the utility incision. 
Open-thoracotomy  lobectomy  was  performed  via  standard 
posterolateral  thoracotomy  through  the  fourth  or  fifth  inter-
costal  space.  Bronchial  division  was  carried  out  using 
staplers. Mediastinal lymph node dissection was performed in 
all  patients  regardless  of  the  surgical  approaches,  and  it  con-
sisted of en bloc resection of all nodes at stations of 2R, 4R, 
7,  8,  9,  10,  and  11R  for  right-sided  tumor,  and  nodes  at  sta-
t i o n s  o f  4 L ,  5 ,  6 ,  7 ,  8 ,  9 ,  1 0  a n d  1 1 L  f o r  l e f t - s i d e d  t u m o r .
Descriptive  statistics  were  used  to  describe  the  patients’ 
characteristics  and  outcomes.  The  normally  distributed  con-
tinuous  data  were  expressed  as  means±standard  deviations. 
Categorical  data  were  expressed  as  counts  and  proportions. 
T h e  s t u d e n t  t  t e s t s  a n d  t h e  ×2  test  or  Fisher  exact  test  were 
used  to  compare  the  continuous  and  categorical  variables,  re-
spectively.  Overall  survival  (OS)  was  defined  as  the  time 
from the date of surgery to the last date of follow-up for pa-
tients  who  remained  alive,  or  to  the  date  of  death.  Disease- 
free survival (DFS) was defined as the time from the date of 
surgery to the date of recurrence recognition, death, or to the 
end  of  observation.  Survival  curves  were  plotted  using  the 
Kaplan-  Meier  method  and  compared  univariately  using  the 
log-rank test. All statistical testing was done at the two-sided 
0.05  level  of  p-value  using  SAS
Ⓡ 9 . 1  ( S A S  I n s t i t u t e  I n c . ,  
Cary,  NC,  USA).
RESULTS
From  December  2003  and  December  2007,  1,469  patients 
underwent  curative  resection  for  NSCLC  in  our  institution, 
and  among  them,  878  were  found  to  have  pathologic  stage  I 
lung  cancer.  VATS  lobectomy  was  performed  in  268  cases, 
and  216  of  them  had  pathologic  stage  I  lung  cancer.  Among 
the  878  patients,  529  patients  were  included  for  analysis, 
which  consisted  of  373  open-thoracotomy  patients  and  156 
VATS patients. Patients with co-morbidity which could affect 
the  survival  or  postoperative  courses,  such  as  history  of  ma-
lignancy or co-existing malignancy of other organs, end stage 
renal disease, heart failure, liver cirrhosis, and pulmonary dis-
ease  with  moderate  to  severe  dysfunction,  were  excluded 
from  patient  enrollment.  Among  the  patients  with  VATS  lo-
bectomy, 17 patients, who underwent surgery with rib spread-
ing  in  our  early  experience  of  VATS  practice,  were  also 
excluded. There were 3 cases of open-thoracotomy conversion 
from  VATS  procedures  during  the  same  period.  In  two  of 
them,  the  operator  decided  to  open  the  chest  because  the  in-
traoperative  frozen  biopsy  of  lymph  node  revealed  tumor 
metastasis. In  one  patient, there  happened  the segmental arte-
rial  injury  during  VATS  procedure,  which  forced  conversion 
to  thoracotomy.  These  patients  were  excluded  from  analysis.
After the patients were matched by age, gender and patho-
logic  stage,  there  remained  272  patients  eligible  for  analysis, 
136  in  each  group.  The  mean  age  of  patients  in  both  groups 
was 59.5 years, and each groups consisted of 70 men and 66 
women,  and  80  pathologic  stage  IA  and  56  pathologic  stage 
IB. There was no statistical difference in preoperative clinical 
characteristics  between  the  two  groups.  Distribution  of  tumor 
pathology,  preoperative  pulmonary  function,  postoperative  ad-
juvant  therapy  and  pre-existing  co-morbidities  of  the  patients 
were  compared,  and  there  was  no  significant  difference  in VATS Lobectomy for Pathologic Stage I Non-Small Cell Lung Cancer
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Table 2. Postoperative complications
Thoracotomy 
(30  cases/22  pts)
VATS 
(19  cases/17  pts)
Prolonged  air  leakage
Pneumonia
ALI/ARDS
Vocal  cord  palsy
Chylothorax
Atrial  fibrillation
Delirium
AMI
ARF
Postoperative  bleeding
11
 2
 5
 4
 2
 2
 1
 1
 1
 1
8
1
1
2
2
2
1
1
1
0
VATS=Video-assisted  thoracic  surgery;  ALI=Acute  lung  injury; 
ARDS=Acute  respiratory  distress  syndrome;  AMI=Acute  my-
ocardial  infarction;  ARF=Acute  renal  failure.
Fig. 1. Three-year overall survival. The 3-year overall survival 
were 97.4% in open-thoracotomy group (solid line) and 96.6% in 
VATS (Video-assisted thoracic surgery) group (dotted line) (p=0.76). 
OP=Operation.
Fig. 2. Three-year recurrence-free survival. The 3-year recur-
rence-free survival were 81.8% in open-thoracotomy group (solid 
line) and 85.3% in VATS (Video-assisted thoracic surgery) group 
(dotted line) (p=0.43). OP=Operation.
Table 3. Recurrence patterns according to pathologic stage
Thoracotomy 
(n=20)
VATS  (n=13)
Stage  IA
Locoregional
Distant
Both
Stage  IB
Locoregional
Distant
Both
4
2
1
3
5
5
2
3
0
2
4
2
VATS=Video-assisted  thoracic  surgery.
these  variables  between  the  two  groups.
There  were  2  operative  mortality  in  the  entire  VATS  lo-
bectomy  group  during  the  same  period  (2/268,  0.74%),  and 
one  with  pathologic  stage  I  was  excluded  from  the  analysis 
during  the  matching  process.  In  the  two  matching  groups, 
there  was  no  in-hospital  mortality  related  to  the  operation. 
There  were  49  postoperative  complications  in  39  patients  (30 
cases/22  patients  in  open-thoracotomy  group,  19  cases/17  pa-
tients  in  VATS  group.  There  was  no  statistical  difference  in 
postoperative  complications  betw e e n  t h e  t w o  g r o u p s  ( p = 0 . 6 5 ,  
odds  ratio=1.19).  Table  2  shows  the  details  of  complications 
in  each  group.
The  mean  length  of  hospital  stay  of  the  patients  who  un-
derwent  VATS  lobectomy  was  significantly  shorter,  by  2 
days,  than  that  of  open-thoracotomy  group  (8.8±6.5  days  vs. 
6.3±3.3  days,  p＜0.05).
The  median  follow-up  period  was  27.7±13.1  months  (2∼
58.2  months),  and  median  follow-up  of  open-thoracotomy 
group  and  VATS  group  were  30.9±13.4  months  (2.6∼57.8 
months)  and  24.6±12.1  months  (2.0∼58.2  months),  respec-
tively.
The overall 3-year  survival was  97.4% in  thoracotomy and 
96.6%  in  VATS  groups.  There  was  no  significant  survival Joon Suk Park, et al
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difference  between  the  two  groups  (p=0.76)  (Fig.  1).
During  the  follow-up  period,  twenty  patients  (20/136, 
14.7%)  in  open-thor a c o t o m y  g r o u p  e x p erienced  tumor  re-
currence,  including  7  with  loco-regional  recurrence  and  13 
with  distant  metastasis.  In  VATS  group,  13  patients  (13/136, 
9.6%) experienced tumor recurrence, including 4 with loco-re-
gional  recurrence  and  9  with  distant  metastasis.  Table  3 
shows  the  recurrence  pattern  of  each  group,  according  to 
pathologic  stage.
Three-year recurrence-free survival was 81.8% in open-tho-
racotomy  group  and  85.3%  in  VATS  group.  There  was  no 
significant  difference  in  recurrence  between  the  two  groups 
(p=0.43)  (Fig.  2).
DISCUSSION
Since  VATS  was  first  introduced  for  pulmonary  resection 
of  malignant  lung  tumors  in  1992,  surgical  technique  of  this 
minimally  invasive procedure  has  been  markedly refined,  and 
VTAS  lobectomy  for  lung  cancer  has  been  increasingly 
performed.  Many  large  series  on  the  feasibility  of  VATS  ap-
proach  have  been  published.  Most  of  these  reports  have  em-
phasized  on  the  benefit  of  VATS  lobectomy  in  terms  of  bet-
ter cosmesis, less surgical trauma, reduced postoperative pain, 
lower  complication,  and  shorter  hospital  stay  resulting  in  re-
duced  cost  [2-13].  The  ‘Cancer  and  Leukemia  Group  B 
(CALGB)  39802’  prospective  multi-institutional  study  eval-
uated  the  technical  feasibility  and  safety  of  VATS  lobectomy 
for  early-stage  non-small-cell  lung  cancer  (NSCLC),  and  re-
vealed that the procedure can be performed with low morbid-
ity  and  mortality  rates.  The  failure-free  survival  after  VATS 
lobectomy for T1N0 lesion was 91% at 1 year and 78% at 2 
years  [14].  Furthermore,  a  recent  meta-analysis  of  the  reports 
on  the  safety  and  efficacy  of  VATS  lobectomy  concluded 
that  it  could be a  safe alternative  to open-thoracotomy  lobec-
tomy  [15].  However,  some  surgeons  still  hesitate  to  adopt 
VATS lobectomy for lung cancer, and this is why VATS lo-
bectomy  accounts  for  only  less  than  20%  of  all  lobectomies 
performed  in  the  United  States  [1,15-18].  Main  concern  is 
about  whether  VATS  lobectomy  can  accomplish  the  onco-
logic  results  comparable  to  conventional  open-thoracotomy 
lobectomy.  There  certainly  are  several  controversial  issues 
specific  to  cancer  surgery  employing  VATS,  such  as  1)  un-
der-staging  or  mis-diagnosis  due  inadequate  lymph  node  dis-
section  or  undetected  nodules  in  other  lobes,  which  could 
well  be  manually  detected  during  open-thoracotomy  proce-
dure,  2)  tumor  dissemination  during  the  VATS  manipulation, 
and  3)  the  risk  of  leaving  residual  tumors  at  the  resection 
margin.  Despite  these  concerns,  recent  studies  on  the  onco-
logic  outcome  of  VATS  lobectomy  in  comparison  with 
open-thoracotomy  lobectomy  have  revealed  the  superiority  of 
VATS,  not  only  in  the  early  postoperative  results,  such  as 
postoperative  pain,  morbidity,  and  hospital  stay,  but  also  in 
terms of long term outcomes, such as quality of life and sur-
vival,  although  statistical  power  of  these  studies  are  some-
what  undermined  by  the  small  number  of  patients  [19-21]. 
In this retrospective study, for the valid comparison of two 
different  groups  and  elimination  of  possible  bias  as  much  as 
possible,  we  performed  propensity  score  matching  of  two 
groups on the covariates of age, sex, underlying co-morbidity, 
and  pathologic  staging.  Other  variables  which  can  influence 
the  operative  results  and  patient’s  survival,  such  as  pre-
operative  pulmonary  function,  postoperative  complications, 
and postoperative adjuvant therapies, were compared to verify 
that  there  was  no  statistical  difference  between  the  two 
groups. By this method, we ascertained that comparable oper-
ative  results  could  be  achieved  by  VATS  lobectomy  in  com-
parison  to  conventional  open-thoracotomy.  The  occurrence  of 
postoperative complications was not different between the two 
groups. Furthermore, the hospital stay was significantly short-
er  in  VATS  group,  which  could  contribute  greatly  to  low-
ering  the  cost  and  endeavor  of  postoperative  care.
Three-year  overall  survival  and  three-year  recurrence  free 
survival  of  VATS  group  was  equivalent  to  that  of  open-thor-
acotomy group. Locoregional recurrence rate was not high ei-
t h e r  i n  V A T S  g r o u p .  T h e  m e a n  n u m b e r  o f  d i s s e c t e d  l y m p h  
nodes  in  VATS  group  was  15.0±8.3.  The  same  technique  of 
lymph  node  dissection  with  conventional  open-thoracotomy 
was  applied  to  VATS  lobectomy,  which  consisted  of  en  bloc 
resections  of  all  nodes  at  stations  of  2R,  4R,  7,  8,  9,  and 
10R for right-sided tumors and nodes at stations of 4 L, 5, 6, 
7, 8, 9 and 10 L for left-sided tumors. During the same peri-
o d ,  2 6 8  V A T S  l o b e c t o m i e s  w e r e  p e r f o r m e d  f o r  c l i n i c a l  s t a g e  
I N SCLC, an d 52 o f them w er e fo und  to  h ave metastatic re-VATS Lobectomy for Pathologic Stage I Non-Small Cell Lung Cancer
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gional and/or mediastinal lymph node. This up-staging from a 
lower  preoperative  clinical  stage  to  a  higher  postoperative 
pathologic  stage  could  be  achieved  due  to  complete  lymph 
node  dissection. 
Our  study  has  several  limitations.  First,  since  this  is  a  ret-
rospective  study,  our  results  should  be  interpreted  with  cau-
tion  even  though  we  have  conducted  propensity  matching 
analysis.  Prospective  randomized  trials  are  needed  for  more 
conclusive results. Second, we have chosen to perform VATS 
lobectomy by individual surgeon’s preference. This can cause 
unrevealed  bias  and  might  have  predisposed  patients  under-
going  VATS  lobectomy  to  outcomes  more  favorable  than 
those  undergoing  open-thoracotomy.  It  should  also  be  noted 
that  VATS procedures which were  converted to open surgery 
were  not  included  in  this  study.  Third,  VATS  group,  which 
includes  patients  with  peripheral  lesion  almost  exclusively, 
consisted  of  mostly  adenocarcinoma  patients.  On  the  other 
hand,  open-thoracotomy  group  had  more  patients  with  squ-
amous  cell  carcinoma  patient,  because  many  patients  of  this 
group  has  endobronchial  lesion.  This  difference  might  have 
influenced the survival results. Fourth, follow-up duration was 
relatively  short,  and  we  were  only  able  to  estimate  3-year 
survival, which made it difficult to conclude if recurrence-free 
survival after VATS lobectomy was truly comparable to thor-
acotomy lobectomy. Longer-term survival data may be neces-
sary  to  verify  our  hypothesis.
CONCLUSION
Our  results  suggest  that  VATS  lobectomy  for  pathologic 
stage  1  NSCLC  is  feasible  and  safe  with  shorter  hospital 
stay, low postoperative morbidity and mortality, and favorable 
survival  comparable  with  conventional  open-thoracotomy  lo-
bectomy,  for  the  patients  with  pathologic  stage  I  NSCLC.
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